| Quarterly Financials | Mar 2015 | Jun 2015 | Sept 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sept 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sept 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
Revenue  | 504 | 582 | 1,003 | 918 | 630 | 737 | 880 | 777 | 742 | 648 | 797 | 840 | 854 | 863 | 1,129 | 1,022 | 930 | 952 | 1,241 | 1,210 | 1,243 | 1,342 | 1,460 | 1,317 | 1,306 | 1,328 | 1,313 | 1,291 | 1,426 | 1,263 | 1,475 | 1,510 | 1,407 | 1,498 | 1,605 | 1,634 | 1,521 | 1,564 | 1,678 | 1,703 | 1,784 |
| Expenses | 405 | 478 | 629 | 532 | 484 | 580 | 702 | 632 | 606 | 547 | 610 | 653 | 680 | 712 | 825 | 776 | 749 | 757 | 895 | 884 | 926 | 934 | 1,014 | 949 | 960 | 1,090 | 1,054 | 1,030 | 1,268 | 1,255 | 1,244 | 1,274 | 1,203 | 1,288 | 1,387 | 1,364 | 1,257 | 1,325 | 1,409 | 1,433 | 1,498 |
| EBITDA | 99 | 103 | 375 | 386 | 146 | 158 | 178 | 146 | 136 | 102 | 187 | 188 | 174 | 151 | 305 | 246 | 181 | 195 | 346 | 326 | 318 | 408 | 447 | 368 | 346 | 238 | 259 | 261 | 158 | 9 | 231 | 236 | 205 | 210 | 218 | 269 | 263 | 239 | 270 | 270 | 286 |
| Operating Profit % | 19 % | 18 % | 37 % | 42 % | 23 % | 21 % | 20 % | 19 % | 18 % | 16 % | 23 % | 22 % | 20 % | 18 % | 27 % | 24 % | 19 % | 20 % | 28 % | 27 % | 23 % | 30 % | 30 % | 28 % | 25 % | 18 % | 18 % | 19 % | 10 % | 1 % | 16 % | 16 % | 14 % | 13 % | 13 % | 16 % | 17 % | 15 % | 15 % | 15 % | 15 % |
| Depreciation | 11 | 13 | 13 | 22 | 24 | 19 | 21 | 21 | 22 | 22 | 26 | 26 | 32 | 28 | 29 | 29 | 30 | 35 | 36 | 42 | 44 | 42 | 44 | 47 | 51 | 53 | 55 | 56 | 123 | 67 | 68 | 67 | 74 | 66 | 68 | 69 | 70 | 69 | 71 | 70 | 69 |
| Interest | 0 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 2 | 6 | 6 | 5 | 5 | 7 | 7 | 8 | 7 | 5 | 2 | 3 | 2 | 5 | 4 | 7 | 9 | 12 | 15 | 14 | 14 | 16 | 15 | 11 | 13 | 19 | 22 | 25 |
| Profit Before Tax | 89 | 91 | 362 | 364 | 120 | 137 | 157 | 124 | 112 | 79 | 161 | 161 | 141 | 122 | 270 | 211 | 146 | 155 | 303 | 276 | 266 | 360 | 398 | 318 | 292 | 183 | 200 | 201 | 29 | -67 | 151 | 155 | 116 | 130 | 135 | 185 | 183 | 157 | 180 | 178 | 192 |
| Tax | 18 | 19 | 73 | 95 | 29 | 33 | 37 | 37 | 19 | 12 | 39 | 30 | 47 | 32 | 70 | 42 | 23 | 36 | 52 | 49 | 62 | 66 | 73 | 33 | 49 | 24 | 36 | 29 | 7 | -2 | 18 | 33 | -36 | 9 | -2 | 4 | 5 | 23 | 27 | 40 | 35 |
| Net Profit | 70 | 72 | 289 | 269 | 91 | 104 | 120 | 87 | 93 | 67 | 122 | 131 | 94 | 90 | 200 | 169 | 124 | 120 | 250 | 227 | 204 | 293 | 325 | 286 | 243 | 158 | 164 | 172 | 22 | -66 | 133 | 122 | 153 | 121 | 137 | 180 | 178 | 135 | 153 | 138 | 157 |
| EPS in ₹ | 3.73 | 3.72 | 15.30 | 14.26 | 4.82 | 5.50 | 6.36 | 4.59 | 4.94 | 3.54 | 6.45 | 6.93 | 4.98 | 4.80 | 10.61 | 9.01 | 6.58 | 6.56 | 13.06 | 12.42 | 11.93 | 15.99 | 17.24 | 14.88 | 12.75 | 8.37 | 8.34 | 8.74 | 1.11 | -3.35 | 6.78 | 6.20 | 7.76 | 6.14 | 6.95 | 9.23 | 9.07 | 6.84 | 7.79 | 7.01 | 7.98 |
Alembic Pharmaceuticals
972.10
+0.90
(0.09%)
There are 2 new updates from the company15 hours ago
View
Market Cap
19,107.90 Cr
EPS
31.33
PE Ratio
33.33
Dividend Yield
1.13 %
Industry
Healthcare52 Week High
1,303.90
52 Week Low
725.20
PB Ratio
3.68
Debt to Equity
0.13
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from11 analysts
Company News
View All News
Alembic Pharma Receives USFDA Approval for Amlodipine and Atorvastatin Tablets21 hours ago
Alembic Pharmaceuticals has announced that it has received final approval from the United States Food and Drug Administration (USFDA) for its Amlodipine and Atorvastatin Tablets. This approval allows the company to market these medications in the US market.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,683.60 | #1 4,03,952.00 | 35.21 | #1 49,887.20 | 12.06 | #1 9,648 | -18.99 | 40.74 | |
6,483.00 | 1,72,103.30 | 78.53 | 8,184.00 | 0.89 | 1,600 | 23.05 | 63.44 | |
1,484.20 | 1,19,866.20 | 22.74 | 26,520.70 | 14.17 | 4,155 | 30.28 | 47.86 | |
3,174.70 | 1,07,446.30 | 55.70 | 10,785.70 | 11.59 | 1,656 | 10.91 | 43.82 | |
1,230.10 | 1,02,646.40 | #1 18.15 | 28,905.40 | 12.36 | 5,578 | 21.14 | 62.40 | |
2,432.40 | 1,00,355.60 | 50.56 | 10,615.60 | 19.57 | 1,942 | -10.91 | 44.37 | |
908.60 | 91,426.40 | 19.56 | 19,831.50 | 13.82 | 3,831 | -0.19 | 56.78 | |
1,978.90 | 90,344.90 | 27.54 | 20,141.50 | #1 19.94 | 1,936 | #1 112.49 | 44.10 | |
1,197.10 | 69,527.80 | 19.71 | 29,559.20 | 17.55 | 3,169 | -10.04 | 50.83 | |
30,795.00 | 65,437.20 | 46.30 | 6,097.20 | 10.80 | 1,201 | 27.83 | 54.40 |
Automatic Screeners on ScanX
Forecast
Actual
Growth Rate
Revenue Growth
10.64 %
Net Income Growth
80.06 %
Cash Flow Change
10.95 %
ROE
63.22 %
ROCE
54.94 %
EBITDA Margin (Avg.)
22.28 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 |
| Fixed Assets | 547 | 708 | 799 | 993 | 1,159 | 1,552 | 1,788 | 1,798 | 2,398 | 2,547 |
| Current Assets | 891 | 1,511 | 1,373 | 1,825 | 1,958 | 2,463 | 2,652 | 2,861 | 2,910 | 3,079 |
| Capital Work in Progress | 83 | 93 | 396 | 1,010 | 1,551 | 1,846 | 2,183 | 2,304 | 601 | 524 |
| Investments | 0 | 53 | 50 | 42 | 49 | 18 | 236 | 118 | 96 | 93 |
| Other Assets | 1,011 | 1,575 | 1,444 | 1,896 | 2,019 | 2,573 | 2,502 | 2,902 | 3,087 | 3,282 |
| Total Liabilities | 1,641 | 2,429 | 2,689 | 3,941 | 4,778 | 5,989 | 6,709 | 7,122 | 6,183 | 6,446 |
| Current Liabilities | 684 | 747 | 693 | 1,144 | 1,490 | 1,752 | 1,281 | 1,717 | 1,637 | 1,455 |
| Non Current Liabilities | 72 | 84 | 94 | 576 | 570 | 1,047 | 361 | 168 | 175 | 172 |
| Total Equity | 885 | 1,597 | 1,902 | 2,220 | 2,718 | 3,190 | 5,067 | 5,238 | 4,371 | 4,818 |
| Reserve & Surplus | 847 | 1,560 | 1,865 | 2,182 | 2,681 | 3,182 | 5,028 | 5,198 | 4,331 | 4,779 |
| Share Capital | 38 | 38 | 38 | 38 | 38 | 38 | 39 | 39 | 39 | 39 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 3 | 417 | -286 | -69 | 115 | -127 | 26 | -37 | 14 | 45 |
| Investing Activities | -256 | -307 | -486 | -884 | -756 | -731 | -840 | -372 | -448 | -321 |
| Operating Activities | 172 | 948 | 329 | 312 | 812 | 449 | 1,463 | 552 | 724 | 803 |
| Financing Activities | 87 | -224 | -129 | 503 | 59 | 155 | -597 | -217 | -262 | -438 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 69.48 % | 69.48 % | 69.48 % | 69.48 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.61 % | 69.67 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 4.52 % | 4.46 % | 4.32 % | 3.94 % | 4.17 % | 3.94 % |
| DIIs | 10.92 % | 11.17 % | 11.36 % | 11.56 % | 11.69 % | 12.06 % | 12.43 % | 12.76 % | 13.31 % | 13.40 % | 13.93 % | 14.50 % | 15.38 % | 15.47 % | 16.05 % | 16.06 % | 16.43 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 10.99 % | 10.78 % | 11.43 % | 9.57 % | 9.22 % | 8.91 % | 9.12 % | 9.21 % | 9.08 % | 8.98 % | 8.24 % | 8.00 % | 7.41 % | 7.48 % | 7.36 % | 7.26 % | 7.07 % |
| Others | 8.61 % | 8.57 % | 7.73 % | 9.39 % | 9.47 % | 9.41 % | 8.84 % | 8.42 % | 8.00 % | 8.01 % | 8.22 % | 3.37 % | 3.14 % | 3.13 % | 3.04 % | 2.90 % | 2.88 % |
| No of Share Holders | 0 | 0 | 99,809 | 1,01,686 | 1,23,059 | 1,10,038 | 1,06,437 | 1,01,457 | 1,03,811 | 97,607 | 89,552 | 85,212 | 76,567 | 74,829 | 91,429 | 93,944 | 91,336 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 4 | 4 | 5.5 | 10 | 14 | 10 | 8 | 11 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.73 | 0.74 | 1.03 | 1.04 | 1.89 | 2.13 | 0.81 | 1.18 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 06 May 2025 |  Quarterly Result Announcement | NA | 06 May 2025 | 849.90 | 905.45 |
| 03 Feb 2025 | Quarterly Result Announcement | NA | 03 Feb 2025 | 1,029.95 | 937.10 |
| 07 Nov 2024 | Quarterly Result Announcement | NA | 07 Nov 2024 | 1,182.75 | 1,139.20 |
| 22 Jul 2024 |  Annual General Meeting | NA | 22 Jul 2024 | 845.20 | 1,079.55 |
| 15 Jul 2024 |  Dividend | ₹ 11.00 /share | 15 Jul 2024 | 1,001.85 | 984.60 |
| 28 Jul 2023 | Dividend | ₹ 8.00 /share | 28 Jul 2023 | 560.55 | 732.15 |
| 18 Aug 2022 | Dividend | ₹ 10.00 /share | 17 Aug 2022 | 781.50 | 656.10 |
| 21 Jul 2021 | Dividend | ₹ 14.00 /share | 19 Jul 2021 | 983.60 | 939.65 |
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
15 hours ago
15 hours agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release21 hours ago
21 hours agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication2 days ago
2 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation3 days ago
3 days agoAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation7 days ago
7 days agoAnnouncement under Regulation 30 (LODR)-Newspaper Publication8 days ago
8 days agoPlease Find Attached Herewith Copy Of Newspaper Advertisement8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Change in Management8 days ago
8 days agoAnnouncement under Regulation 30 (LODR)-Press Release / Media Release8 days ago
8 days agoCompliances-Reg.24(A)-Annual Secretarial Compliance10 days ago
10 days agoAnnouncement under Regulation 30 (LODR)-Earnings Call TranscriptMay 12, 2025
May 12, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 07, 2025
May 07, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeMay 06, 2025
May 06, 2025Announcement Under Regulation 30 Of SEBI LODRMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/sMay 06, 2025
May 06, 2025Financial Results For The Quarter And Financial Year Ended 31St March 2025May 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Investor PresentationMay 06, 2025
May 06, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 06, 2025
May 06, 2025Board Meeting Outcome for Please Find Attached Herewith The Outcome Of Board MeetingMay 06, 2025
May 06, 2025Board Meeting Outcome for Please Find Attached Herewith The Outcome Of Board MeetingMay 06, 2025
May 06, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations 2015")May 05, 2025
May 05, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseMay 02, 2025
May 02, 2025Announcement Under Regulation 30 Of SEBI Regulations 2015Apr 29, 2025
Apr 29, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Apr 26, 2025
Apr 26, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationApr 25, 2025
Apr 25, 2025Intimation For Change Of Email And Website Address Of The Registrar And Share Transfer Agent (RTA) Of The CompanyApr 18, 2025
Apr 18, 2025Board Meeting Intimation for Board Meeting To Consider Audited Financial Results For The Quarter And Financial Year Ended 31St March 2025Apr 18, 2025
Apr 18, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 17, 2025
Apr 17, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 09, 2025
Apr 09, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 04, 2025
Apr 04, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationApr 03, 2025
Apr 03, 2025Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseApr 01, 2025
Apr 01, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Successful Completion Of USFDA Inspection At Alembic Pharmaceuticals Limited API-III Facility At KarakhadiMar 21, 2025
Mar 21, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Mar 17, 2025
Mar 17, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportMar 17, 2025
Mar 17, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotMar 17, 2025
Mar 17, 2025Completion Of USFDA Inspection At Alembic Pharmaceuticals LimitedS Bioequivalence Facility At VadodaraMar 07, 2025
Mar 07, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMar 06, 2025
Mar 06, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 19, 2025
Feb 19, 2025Alembic Pharmaceuticals Limited Receives Establishment Inspection Report (EIR) For Its Solid Oral Formulation Facility (F-4) At JarodFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Feb 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotFeb 12, 2025
Feb 12, 2025Announcement under Regulation 30 (LODR)-Change in ManagementFeb 11, 2025
Feb 11, 2025Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015Feb 11, 2025
Feb 11, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 04, 2025
Feb 04, 2025Announcement under Regulation 30 (LODR)-RetirementFeb 04, 2025
Feb 04, 2025Integrated Filing (Financial)Feb 03, 2025
Feb 03, 2025Technical Indicators
RSI(14)
Neutral 62.23
ATR(14)
Less Volatile 37.69
STOCH(9,6)
Neutral 62.42
STOCH RSI(14)
Neutral 40.63
MACD(12,26)
Bullish 7.36
ADX(14)
Strong Trend 29.03
UO(9)
Bearish 55.92
ROC(12)
Uptrend And Accelerating 8.39
WillR(14)
Neutral -40.74
About Alembic Pharmaceuticals
Alembic Pharmaceuticals is an India-based company that manufactures and markets generic pharmaceutical products globally. It operates in India Formulations, International Generics, and Active Pharmaceutical Ingredients (API) segments. The company has state-of-the-art research and manufacturing facilities approved by regulatory authorities, including the US FDA. Alembic produces a range of generics across chronic segments, including Dermatology, Anti-Infective, Cardiology, and Anti-Diabetic therapies. The company has manufacturing facilities in Gujarat and Sikkim, with research and development centers in Vadodara, Hyderabad, and New Jersey. Alembic has expanded its operations through acquisitions, joint ventures, and international subsidiaries, focusing on developing and marketing generic drugs in various global markets.
Chairperson NameChirayu R Amin
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
